Emyria's MDMA-AT program delivers promising results for PTSD treatment

Emyria Limited (ASX:EMD) has released promising interim clinical results from its MDMA-assisted therapy (MDMA-AT) for Post-Traumatic Stress Disorder (PTSD) program. The analysis of the first eight patients completing the program has demonstrated substantial improvement in PTSD symptoms, with a clinically and statistically significant average reduction of 33 points in PCL-5 scores. Additionally, all patients reported substantial gains in quality of life, with a mean improvement of 22 points on the ReQoL scale. Emyria continues to evolve its leading care programs by actively collecting and applying Real-World Data, setting the standard for PTSD care and reinforcing its global leadership in developing promising new mental health treatments.

Executive Commentary on Promising Interim Results

Michael Winlo, CEO of Emyria, stated, 'These early Real-World results from our MDMA-Assisted Therapy program highlight the significant potential of this approach for PTSD care and provide an early indication of its effectiveness in real clinical settings beyond controlled trials. Emyria is uniquely positioned to lead the global development and refinement of this treatment as Australia is currently the only jurisdiction permitting these therapies under stringent oversight. We believe we have a substantial head start in gathering crucial Real-World Data and refining the approach to fully realize the potential of MDMA-AT thereby helping patients and also advancing the therapy's ongoing improvement.'

Summary of Emyria's Interim Clinical Results and Future Plans

Emyria's interim clinical results have shown a significant reduction in PTSD symptoms and a marked improvement in patients' quality of life through its MDMA-assisted therapy program. The company plans to leverage existing revenues to fund the expansion of its programs and is actively engaging with private hospitals and third-party payers to broaden access and secure reimbursement. With a strategic focus on scalable expansion, data-driven care, and advancing regulatory and reimbursement pathways, Emyria aims to become a global leader in the delivery and development of new treatments for mental health and select neurological conditions. The findings are particularly significant for the estimated 6-7% of adults suffering from PTSD, many of whom struggle with treatment resistance to conventional medications. Emyria's program is strategically positioned to meet this demand, addressing a large, unmet need in PTSD care. The company's long-term vision involves creating new IP for long-term value creation while delivering immediate patient benefits. Emyria invites investors to learn more about these results and the company's future plans at upcoming presentations and conferences.